In June 2007, Memory Pharmaceuticals expanded its nicotinic alpha-7 receptor agonist agreement with Roche to support this Phase 2a trial of MEM 3454 in CIAS. The expanded agreement provides that Roche ...
MONTVALE, N.J., Nov. 2 -- Memory Pharmaceuticals Corp. today announced positive top-line data from the randomized, placebo-controlled, multi-center Phase 2a proof-of-concept trial of MEM 3454, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback